Companies
The following companies will participate in the third Swiss Equity biotech day with their own company presentation. Please click "Read more..." for the complete company profile or the logo to visit the company's website.
 |
| Actelion Pharmaceuticals Ltd. |
| Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer®, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. |
| read more... |
|
| |
|
| |
 |
| Addex Pharmaceuticals Ltd. |
| Addex Pharmaceuticals discovers and develops allosteric modulators for human health. Allosteric modulators are a different kind of orally available small molecule therapeutic agent, which we believe will offer patients better results than classical drugs. |
| read more... |
|
| |
|
| |
 |
| Anergis SA |
| Anergis is a Swiss biopharmaceutical company developing ultra-fast and safe specific immunotherapy treatments for patients with allergies. Anergis technology of Contiguous Overlapping Peptides (“COPs”) generates multiple medically and commercially attractive projects. |
| read more... |
|
| |
|
| |
 |
| Arrayon Biotechnology SA |
| Adequately immobilizing biomolecules onto surfaces is a key prerequisite for the success of many innovative bioanalytical and medical device products. Arrayon’s patented linker polymer (OptoDex®) and proprietary surface functionalization technologies cover a large scope of applications: from robust quantitative bio-analytics for in vitro diagnostics to bio-functionalization of surfaces of implants and medical devices. |
| read more... |
|
| |
|
| |
 |
| COSMO Pharmaceuticals S.p.A. |
| Cosmo Pharmaceuticals ("Cosmo”) is a speciality pharmaceutical company that aims to become a global leader in the market of optimised therapies for selected gastro-intestinal (“GI”) diseases. Cosmo’s products address all stages of GI disease. |
| read more... |
|
| |
|
| |
 |
| Delenex Therapeutics AG |
| Delenex Therapeutics is a new private Zurich based clinical stage Biotechnology Company focusing on the research and development of single chain antibody fragments to deliver next generation therapeutics. |
| read more... |
|
| |
|
| |
 |
| Evolva Holding SA |
| Evolva's proprietary discovery technology platform uses a "disruptive" technological approach to the creation of novel small compounds that differs sharply from the prevailing synthetic chemistry and protein engineering approaches in the pharmaceutical industry today. |
| read more... |
|
| |
|
| |
 |
| Glenmark Pharmaceuticals Ltd. (GPL) |
| Glenmark Pharmaceuticals Limited is a research-driven, global, integrated pharmaceutical company. It is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity) with eight molecules in various stages of clinical development. |
| read more... |
|
| |
|
| |
 |
| ImmuPharma AG |
| Immupharma plc (LSE:IMM) is a drug discovery and development group with its key operations in London and subsidiaries in Mulhouse, France and Basle, Switzerland. The Company aims to develop pioneering drugs to treat serious medical conditionsis in specialist therapeutic areas. |
| read more... |
|
| |
|
| |
 |
| Meddiscovery SA |
| Med Discovery’s mission is the discovery and development of highly specific protein-based therapeutics to treat uro-genital cancers. By combining biological drug discovery expertise with a strong in-house knowledge of the medical urology field, the Company is uniquely positioned to develop novel drugs for urological cancers and other related solid tumors. |
| read more... |
|
| |
|
| |
 |
| Molecular Partners AG |
| Molecular Partners is a privately held biotech company focusing on the commercialization of a novel class of biological drugs known as DARPins. The company is using/exploiting this novel class of protein therapeutics to create medicines for diseases with unmet medical need and to dramatically improve existing therapies. |
| read more... |
|
| |
|
| |
 |
| Newron Pharmaceuticals S.p.A. |
| Newron (SIX: NWRN) is a biopharmaceutical company focused on novel therapies for diseases of the Central Nervous System and pain. It is headquartered in Bresso near Milan, Italy, with fully owned subsidiaries in Basel, Switzerland and Bristol, UK. |
| read more... |
|
| |
|
| |
 |
| NovImmune SA |
| NovImmune SA (‘NovImmune’) is a drug discovery and development company with a focus on therapeutic mAbs for inflammatory diseases and immune-related disorders. |
| read more... |
|
| |
|
| |
|
| Orphanbiotec AG |
| Orphanbiotec is a novel Medical Research Network consisting of a Foundation and a Corporation.
This synergy provides both research and development of new therapies for neglected diseases. |
| read more... |
|
| |
|
| |
 |
| Oxygen Biotherapeutics, Inc. |
| Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine™. The company has developed a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte™) and has out-licensed an implantable glucose sensor. |
| read more... |
|
| |
|
| |
 |
| Pantec Biosolutions AG |
| Pantec Biosolutions is a specialty pharma company with the goal to replace injection based medication of biologicals with the help of a breakthrough transdermal delivery method with multiple applications in selected disease areas. |
| read more... |
|
| |
|
| |
 |
| Pentapharm |
| More than fifty years ago, PENTAPHARM (Basel, Switzerland), started out by specializing in research & development and the production of active ingredients for the pharmaceutical industry. Over the years, the company has grown to encompass not only pharmaceuticals but also blood coagulation diagnostics, as well to the cosmetic industry. |
| read more... |
|
| |
|
| |
 |
| PhenoTec AG |
| PhenoTec AG is pharmaceutical research and consulting company based in CH-Zug, F-Orléans and ZA-Cape Town. The technical know-how of PhenoTtec AG is deployed for research and consulting of preclinical projects with many international pharmaceutical partners. |
| read more... |
|
| |
|
| |
 |
| Santhera Pharmaceuticals Holding AG |
| Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of small-molecule pharmaceutical products for the treatment of severe neuromuscular diseases, an area of high unmet medical need which includes many orphan indications with no current therapy. |
| read more... |
|
| |
|
| |
 |
| SeneXta Therapeutics SA |
| SeneXta is a privately held Swiss biopharmaceutical company engaged in the research and development of therapies for neurodegenerative disorders including Alzheimer’s disease, cognitive impairment secondary to ischemia, and other central nervous system (CNS) disorders. |
| read more... |
|
| |
|
| |
 |
| Synosia Therapeutics AG |
Synosia Therapeutics develops and intends to commercialise innovative products for high unmet medical needs in psychiatry and neurology, including anxiety, Parkinson’s diease and drug dependency and Restless legs syndrome.
The company’s pipeline has six clinical-stage compounds acquired with extensive safety and clinical data from Roche, Novartis and Syngenta. |
| read more... |
|
| |
|
| |
